10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be issuing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $160.3520 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.30) earnings per share. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Stock Down 1.1%

Shares of 10x Genomics stock opened at $19.06 on Thursday. The company has a 50 day moving average price of $18.64 and a 200 day moving average price of $15.37. The firm has a market capitalization of $2.41 billion, a P/E ratio of -30.74 and a beta of 2.24. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $23.56.

Analyst Ratings Changes

TXG has been the subject of several research reports. Piper Sandler lifted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Needham & Company LLC set a $21.00 price target on 10x Genomics in a research report on Monday, January 12th. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. JPMorgan Chase & Co. raised their price objective on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Finally, Barclays upped their target price on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and an average price target of $16.83.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 13,261 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the transaction, the chief executive officer directly owned 1,021,556 shares in the company, valued at approximately $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Taich sold 11,888 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the completion of the sale, the chief financial officer owned 297,385 shares in the company, valued at approximately $5,650,315. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,432 shares of company stock valued at $635,208 over the last ninety days. Company insiders own 9.39% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Certuity LLC acquired a new position in shares of 10x Genomics during the 3rd quarter worth approximately $226,000. Orion Porfolio Solutions LLC purchased a new stake in 10x Genomics in the 2nd quarter worth $158,000. CANADA LIFE ASSURANCE Co raised its position in 10x Genomics by 167.9% during the second quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company’s stock worth $256,000 after acquiring an additional 13,831 shares during the period. Vident Advisory LLC purchased a new position in 10x Genomics during the second quarter valued at $162,000. Finally, M&T Bank Corp purchased a new position in 10x Genomics during the second quarter valued at $241,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.